Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) will report its Q4 and full-year 2023 financial results on February 29, 2024. The company will discuss financial results and business highlights in a conference call and webcast.

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website. 

To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until February 28, 2025.

About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid^® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact:
Julie Downs
media@vcel.com

FAQ

When will Vericel Corporation (VCEL) report its Q4 and full-year 2023 financial results?

Vericel Corporation (VCEL) will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.

How can I access the live webcast of the financial results discussion by Vericel Corporation (VCEL)?

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations.

Where can I find the presentation slides for the conference call by Vericel Corporation (VCEL)?

Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

How long will the replay of the webcast by Vericel Corporation (VCEL) be available?

A replay of the webcast will be available on the Vericel website until February 28, 2025.